PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced ...
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
7 Nov 2019
Analysis of assay used in IMpassion130 to guide treatment of metastatic and adva...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Analysis of assay used in IMpassion130 to guide treatment of metastatic and advanced breast cancers ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
31 Oct 2019
Rectal cancer in Latin America, screening and surgery
Dr. Nitin Mishra - Mayo Clinic, Rochester, USA
Rectal cancer in Latin America, screening and surgery ( Dr. Nitin Mishra - Mayo Clinic, Rochester, USA )
21 Oct 2019
The challenge of detecting NTRK fusions across tumour types
Professor Dr Marc Peeters, Professor Caterina Marchio
The challenge of detecting NTRK fusions across tumour types ( Professor Dr Marc Peeters, Professor Caterina Marchio )
21 Oct 2019
Simplifying molecular subtypes of metastatic gastric cancer
Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain
Simplifying molecular subtypes of metastatic gastric cancer ( Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain )
8 Oct 2019
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural m...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
7 Oct 2019
PARP inhibitors for metastatic breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
PARP inhibitors for metastatic breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )
7 Oct 2019
KATHERINE trial updates for HER2-positive breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
KATHERINE trial updates for HER2-positive breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )
7 Oct 2019
TRITON2: Rucaparib for metastatic castration-resistant prostate cancer
Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Irela...
TRITON2: Rucaparib for metastatic castration-resistant prostate cancer ( Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Ireland )
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )
4 Oct 2019
Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1...
Prof Roy Herbst - Yale Cancer Center, New Haven, USA
Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042 ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )
4 Oct 2019
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast can...
Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )
4 Oct 2019